All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA326)

NICE GUIDANCE ISSUED NOVEMBER 2014

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1414 – June 2014

Imatinib (Glivec®) 100 mg and 400 mg film-coated tablets

Submission by Novartis Pharmaceuticals UK Ltd

Recommendation of AWMSG

Imatinib (Glivec®) is recommended for restricted use within NHS Wales.

Imatinib (Glivec®) should be restricted for use in the following subpopulation within its licensed indication for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT (CD117)-positive gastrointestinal stromal tumours. Patients who have low or very low risk of recurrence should not receive adjuvant treatment.

Imatinib (Glivec®) should be restricted for use in patients who are considered to be at high risk of relapse according to the Miettinen criteria.

Imatinib (Glivec®) is not recommended for use within NHS Wales outside of this subpopulation.

Additional note:

- The evidence supporting this indication was based on treatment duration of 36 months.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1653), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the

NICE accredited
www.nice.org.uk/accreditation

NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Novartis Pharmaceuticals Ltd
Date of first issue	June 2014
Last reviewed	May 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1414: Imatinib (Glivec®) 100 mg and 400 mg film-coated tablets. June 2014.